Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

Benzinga11-08

2024 Financial Guidance

Management reiterates its full year 2024 guidance:

Anticipated Total Net Revenues expected to be between $87 million and $95 million;
Anticipated Operating Expenses expected to remain between $115 million and $120 million;
Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and
Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481870173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481870173","market":"us","top_or_hot":-1,"title":"Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M","media":"Benzinga","content":"<html><body><p><strong>2024 Financial Guidance</strong></p><p>Management reiterates its full year 2024 guidance:</p><ul><li>Anticipated Total Net Revenues expected to be between $87 million and $95 million;</li><li>Anticipated Operating Expenses expected to remain between $115 million and $120 million;</li><li>Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and</li><li>Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/24/11/41839639/y-mabs-anticipates-2024-total-net-revenues-of-87m-95m-vs-consensus-of-91-67m><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated Total Net Revenues expected to be between $87 million and $95 million;Anticipated Operating Expenses expected to ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/24/11/41839639/y-mabs-anticipates-2024-total-net-revenues-of-87m-95m-vs-consensus-of-91-67m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSS","symbol_name":"Total System Services","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/24/11/41839639/y-mabs-anticipates-2024-total-net-revenues-of-87m-95m-vs-consensus-of-91-67m","article_id":"2481870173","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481870173","pubTimestamp":1731065932,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated Total Net Revenues expected to be between $87 million and $95 million;Anticipated Operating Expenses expected to remain between $115","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TSS":"Total System Services","YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs预计2024年总净收入为8700万至9500万美元，而共识为9167万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSS":1,"YMAB":0.9},"content_text":"2024 Financial GuidanceManagement reiterates its full year 2024 guidance:Anticipated Total Net Revenues expected to be between $87 million and $95 million;Anticipated Operating Expenses expected to remain between $115 million and $120 million;Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; andCash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481870173"}